STOCK TITAN

[Form 4] Zimmer Biomet Holdings, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Lori Winkler, Senior Vice President and CHRO of Zimmer Biomet Holdings, reported sales of common stock on September 8, 2025. The Form 4 discloses 1,500 shares sold at a weighted average price of $104.15 per share (individual sale prices ranged from $104.15 to $104.18). After the transactions, Ms. Winkler beneficially owns 6,833 shares, held directly. The sale was reported on the Form 4 filed September 10, 2025, and was executed by an attorney-in-fact on her behalf.

Lori Winkler, Vice President Senior e CHRO di Zimmer Biomet Holdings, ha venduto azioni ordinarie il 8 settembre 2025. Il Modulo 4 indica la cessione di 1.500 azioni a un prezzo medio ponderato di $104,15 per azione (i prezzi individuali di vendita sono variati da $104,15 a $104,18). Dopo tali operazioni, la sig.ra Winkler detiene direttamente 6.833 azioni. La vendita è stata riportata nel Modulo 4 depositato il 10 settembre 2025 ed è stata eseguita da un procuratore a suo nome.

Lori Winkler, vicepresidenta sénior y CHRO de Zimmer Biomet Holdings, registró la venta de acciones ordinarias el 8 de septiembre de 2025. El Formulario 4 revela la venta de 1.500 acciones a un precio medio ponderado de $104,15 por acción (los precios individuales oscilaron entre $104,15 y $104,18). Tras las operaciones, la Sra. Winkler posee directamente 6.833 acciones. La venta fue comunicada en el Formulario 4 presentado el 10 de septiembre de 2025 y fue ejecutada por un apoderado en su nombre.

로리 윙클러(Lori Winkler)님은 Zimmer Biomet Holdings의 수석 부사장 겸 CHRO로서 2025년 9월 8일에 보통주를 매도했습니다. 제출된 Form 4에는 가중평균 주당 가격 $104.15에 총 1,500주가 매도된 것으로 기재되어 있으며(개별 매도가는 $104.15에서 $104.18 사이였습니다). 거래 후 윙클러 씨는 직접 6,833주를 보유하고 있습니다. 해당 매도는 2025년 9월 10일 제출된 Form 4에 보고되었으며, 그녀를 대신해 대리인이 실행했습니다.

Lori Winkler, vice-présidente principale et CHRO de Zimmer Biomet Holdings, a déclaré la vente d'actions ordinaires le 8 septembre 2025. Le formulaire 4 indique la cession de 1 500 actions à un prix moyen pondéré de $104,15 par action (les prix de vente individuels variaient de $104,15 à $104,18). Après ces opérations, Mme Winkler détient directement 6 833 actions. La vente a été signalée dans le formulaire 4 déposé le 10 septembre 2025 et a été effectuée par un mandataire en son nom.

Lori Winkler, Senior Vice President und CHRO von Zimmer Biomet Holdings, meldete den Verkauf von Stammaktien am 8. September 2025. Im Formular 4 werden 1.500 verkaufte Aktien zu einem gewichteten Durchschnittspreis von $104,15 je Aktie angegeben (einzelne Verkaufspreise lagen zwischen $104,15 und $104,18). Nach den Transaktionen besitzt Frau Winkler direkt 6.833 Aktien. Der Verkauf wurde im am 10. September 2025 eingereichten Formular 4 gemeldet und von einem Bevollmächtigten in ihrem Namen ausgeführt.

Positive
  • None.
Negative
  • None.

Insights

Routine insider sale; small size relative to typical executive holdings, likely neutral.

The Form 4 shows a direct sale of 1,500 shares by the company CHRO at a weighted average price of $104.15, reducing direct beneficial ownership to 6,833 shares. The filing includes an explanatory note that the sale occurred in multiple transactions on September 8, 2025, and affirms availability of detailed pricing per lot upon request. There is no indication in the filing of any plan-based transaction (no 10b5-1 box checked), no amendment to prior filings, and no derivative activity reported. As presented, this appears to be a routine disposition rather than a material corporate event.

Disclosure complies with Section 16 timing; no governance red flags apparent from this filing alone.

The Form 4 is signed by an attorney-in-fact and contains the required explanatory footnote about weighted average pricing across multiple lots. Reporting identifies the filer as an officer (SVP and CHRO) and indicates direct ownership form. The report does not reference plans or exemptions that would change the interpretation of the sale. From a governance and compliance perspective, the filing meets disclosure requirements and does not reveal related-party transactions or other governance concerns within the document.

Lori Winkler, Vice President Senior e CHRO di Zimmer Biomet Holdings, ha venduto azioni ordinarie il 8 settembre 2025. Il Modulo 4 indica la cessione di 1.500 azioni a un prezzo medio ponderato di $104,15 per azione (i prezzi individuali di vendita sono variati da $104,15 a $104,18). Dopo tali operazioni, la sig.ra Winkler detiene direttamente 6.833 azioni. La vendita è stata riportata nel Modulo 4 depositato il 10 settembre 2025 ed è stata eseguita da un procuratore a suo nome.

Lori Winkler, vicepresidenta sénior y CHRO de Zimmer Biomet Holdings, registró la venta de acciones ordinarias el 8 de septiembre de 2025. El Formulario 4 revela la venta de 1.500 acciones a un precio medio ponderado de $104,15 por acción (los precios individuales oscilaron entre $104,15 y $104,18). Tras las operaciones, la Sra. Winkler posee directamente 6.833 acciones. La venta fue comunicada en el Formulario 4 presentado el 10 de septiembre de 2025 y fue ejecutada por un apoderado en su nombre.

로리 윙클러(Lori Winkler)님은 Zimmer Biomet Holdings의 수석 부사장 겸 CHRO로서 2025년 9월 8일에 보통주를 매도했습니다. 제출된 Form 4에는 가중평균 주당 가격 $104.15에 총 1,500주가 매도된 것으로 기재되어 있으며(개별 매도가는 $104.15에서 $104.18 사이였습니다). 거래 후 윙클러 씨는 직접 6,833주를 보유하고 있습니다. 해당 매도는 2025년 9월 10일 제출된 Form 4에 보고되었으며, 그녀를 대신해 대리인이 실행했습니다.

Lori Winkler, vice-présidente principale et CHRO de Zimmer Biomet Holdings, a déclaré la vente d'actions ordinaires le 8 septembre 2025. Le formulaire 4 indique la cession de 1 500 actions à un prix moyen pondéré de $104,15 par action (les prix de vente individuels variaient de $104,15 à $104,18). Après ces opérations, Mme Winkler détient directement 6 833 actions. La vente a été signalée dans le formulaire 4 déposé le 10 septembre 2025 et a été effectuée par un mandataire en son nom.

Lori Winkler, Senior Vice President und CHRO von Zimmer Biomet Holdings, meldete den Verkauf von Stammaktien am 8. September 2025. Im Formular 4 werden 1.500 verkaufte Aktien zu einem gewichteten Durchschnittspreis von $104,15 je Aktie angegeben (einzelne Verkaufspreise lagen zwischen $104,15 und $104,18). Nach den Transaktionen besitzt Frau Winkler direkt 6.833 Aktien. Der Verkauf wurde im am 10. September 2025 eingereichten Formular 4 gemeldet und von einem Bevollmächtigten in ihrem Namen ausgeführt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Winkler Lori

(Last) (First) (Middle)
345 E. MAIN STREET

(Street)
WARSAW IN 46580

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP and CHRO
3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/08/2025 S 1,500 D $104.15(1) 6,833 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects the weighted average price of 1,500 common shares sold by the reporting person in multiple transactions on September 8, 2025 with sale prices ranging from $104.15 to $104.18 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Matthew R. St. Louis, Attorney-in-Fact for Lori Winkler (power of attorney previously filed) 09/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lori Winkler sell according to the ZBH Form 4?

The Form 4 reports Ms. Winkler sold 1,500 shares of Zimmer Biomet common stock on September 8, 2025.

At what price were the ZBH shares sold by Lori Winkler?

The weighted average sale price was $104.15 per share, with individual sale prices ranging from $104.15 to $104.18.

How many ZBH shares does Lori Winkler own after the sale?

After the reported transactions, Ms. Winkler beneficially owns 6,833 shares, held directly.

When was the Form 4 for these transactions filed?

The Form 4 reporting these transactions was dated and signed on September 10, 2025.

Was this sale part of a 10b5-1 trading plan according to the filing?

The filing does not indicate that the transaction was made pursuant to a 10b5-1 plan (no plan box is checked).
Zimmer Biomet

NYSE:ZBH

ZBH Rankings

ZBH Latest News

ZBH Latest SEC Filings

ZBH Stock Data

20.27B
197.78M
0.15%
98.95%
2.93%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WARSAW